All In Biotech

Drug Trial Radar · NCT06591793

Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Participants With Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jul 2, 2024

Primary completion

Jan 2031

Study completion Jul 2031

Sponsor

Lead sponsor
AAVantgarde Bio SrlIndustry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.

Conditions

  • Usher Syndrome, Type 1B

Interventions

  • AAVB-081Biological

    Single subretinal administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To measure the number and severity of treatment related adverse events following treatment with AAVB-081Time frame: 63 months

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Campania Luigi Vanvitelli

    Naples, Italy

  • Moorfields Eye Hospital

    London, United Kingdom

  • Retina Clinic London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.